Table 1 Patient’s characteristics and AKAP3 status. Stage grouping are based on American Joint Committee on Cancer (AJCC), Estrogen receptor (ER), progesterone receptor (PR), Her2/neu are based on IHC results. Cut point of positivity is based on American Society of Clinical Oncology (ASCO) guideline for IHC
From: AKAP3 correlates with triple negative status and disease free survival in breast cancer
Number of patients | 74 | |
|---|---|---|
Age (median/range) — year | 48 (29–87) | Valid percent |
Follow-up (median/range)—month | 1 8 (1–38) | |
ER status (2 missing, n = 74) | ||
Negative | 40 | 55 |
Positive | 32 | 45 |
PR (2 missing, n = 74) | ||
Negative | 47 | 65 |
Positive | 25 | 35 |
Her2/neu status (2 missing, n = 74) | ||
Negative | 50 | 69 |
Positive | 22 | 31 |
Grade (7 missing, n = 74) | ||
G1 | 6 | 9 |
G2 | 34 | 51 |
G3 | 27 | 40 |
Patient status (3 missing, n = 74) | ||
healthy survival | 50 | 70 |
with events | 21 | 30 |
Stage (5 missing, n = 74) | ||
I | 7 | 10 |
II | 33 | 48 |
III | 21 | 30 |
IV | 8 | 12 |
Tumor Size (6 missing, n = 74) | ||
<=2 | 24 | 35 |
>2 | 44 | 65 |
AKAP3 Tumor (n = 74) | ||
Negative | 47 | 64 |
Positive | 27 | 36 |
AKAP3 Normal adjacent (n = 73) | ||
Negative | 40 | 56 |
Positive | 32 | 44 |
Akap3 Normal Breast (n = 15) | ||
Negative | 8 | 54 |
Positive | 7 | 46 |